Mouse IgG Fc, Tag Free (IG1-M5208) is expressed from human 293 cells (HEK293). It contains AA Val 111 - Lys 324 (Accession # AAK53870.1).
Predicted N-terminus: Val 111
This protein carries no "tag".
The protein has a calculated MW of 24.3 kDa. The protein migrates as 28-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Mouse IgG Fc, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Loaded Mouse FCGRT&B2M Heterodimer Protein, His Tag&Twin-Strep Tag (BLI verified) (Cat. No. FCM-M52W2) on NTA Biosensor, can bind Mouse IgG Fc, Tag Free(Cat. No. IG1-M5208) with an affinity constant of 20 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Mouse FCGRT&B2M Heterodimer Protein, His Tag (BLI verified) (Cat. No. FCM-M52W8) on NTA Biosensor, can bind Mouse IgG Fc, Tag Free(Cat. No. IG1-M5208) with an affinity constant of 14.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.